Tilray is a Canadian pharmaceutical and cannabis company, incorporated in the United States with primary operations headquartered in Toronto, Ontario. Tilray also has operations in Australia, New Zealand, Germany, Portugal and Latin America.

In December 2020, the company announced a merger with Aphria, and will operate under the Tilray name and its ticker symbol on NASDAQ and the Toronto Stock Exchange.

Founded in 2014, Tilray was originally incorporated under the umbrella of Seattle-based Privateer Holdings. In December 2016, Tilray was certified for good manufacturing practices.

In September 2018, Tilray became the first Canadian cannabis company to legally export medical cannabis to the U.S. for a clinical trial. In December 2018, the company signed a deal with Novartis subsidiary Sandoz to sell, distribute and co-brand Tilray’s non-smokable/non-combustible medical cannabis products in legal markets worldwide. On June 19, 2018, Tilray announced the launch of High Park Company which would operate in the adult recreational cannabis market to establish unique adult-use brands in Canada upon its legalization.